{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:33:48Z","timestamp":1790951628318,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.esmoop.2022.100572","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T22:19:28Z","timestamp":1663021168000},"page":"100572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report"],"prefix":"10.1016","volume":"7","author":[{"given":"M.C.","family":"Hardenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garcia Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Grohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.M.","family":"Stiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100572_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918772810","article-title":"Immunotherapy in non-metastatic non-small cell lung cancer: can the benefits of stage IV therapy be translated into earlier stages?","volume":"10","author":"Deslypere","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib3","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib4","series-title":"Lung cancer (non-small-cell, first line)-gefitinib: appraisal consultation document | Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer | Guidance | NICE","year":"2009"},{"key":"10.1016\/j.esmoop.2022.100572_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1758834009338634","article-title":"Adjuvant therapy for resected non-small cell lung cancer","volume":"1","author":"Wozniak","year":"2009","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib6","first-page":"191","article-title":"Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art","volume":"4","author":"Cort\u00e9s","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100572_bib7","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2004.02.109","article-title":"Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer","volume":"22","author":"Hotta","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib8","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.lungcan.2018.07.042","article-title":"Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study","volume":"124","author":"Chouaid","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100572_bib10","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/annonc\/mdu442","article-title":"Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach","volume":"25","author":"Rotolo","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2217\/fon-2020-0280","article-title":"Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer","volume":"16","author":"Nadler","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cllc.2017.10.003","article-title":"Effect of brain metastasis on patient-reported outcomes in advanced NSCLC treated in real-world community oncology settings","volume":"19","author":"Walker","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100572_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2022.100572_bib14","doi-asserted-by":"crossref","first-page":"S2114","DOI":"10.21037\/jtd.2018.06.114","article-title":"Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?","volume":"10","author":"Roviello","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.esmoop.2022.100572_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/jclinpath-2012-201194","article-title":"EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples","volume":"66","author":"Ellison","year":"2013","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.esmoop.2022.100572_bib16","first-page":"1","article-title":"Complete remission of multiple brain metastases in a patient with EGFR-mutated non-small-cell lung cancer treated with first-line osimertinib without radiotherapy","volume":"2020","author":"Ameku","year":"2020","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.esmoop.2022.100572_bib19","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100572_bib21","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib22","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1200\/JOP.2012.000870","article-title":"Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma","volume":"9","author":"Wood","year":"2013","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.esmoop.2022.100572_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.39.28_suppl.236","article-title":"Use of the Delphi method to develop a guideline-based geriatric oncology gap assessment","volume":"39","author":"Plotkin","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fpubh.2020.00457","article-title":"Delphi technique in health sciences: a map","volume":"8","author":"Niederberger","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.esmoop.2022.100572_bib25","author":"Stone Fish"},{"key":"10.1016\/j.esmoop.2022.100572_bib26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1365-2648.2003.02537.x","article-title":"The Delphi technique: myths and realities","volume":"41","author":"Powell","year":"2003","journal-title":"J\u00a0Adv Nurs"},{"key":"10.1016\/j.esmoop.2022.100572_bib27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/0962280207081864","article-title":"Individual- and trial-level surrogacy in colorectal cancer","volume":"17","author":"Buyse","year":"2008","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.esmoop.2022.100572_bib29","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jnci\/djt270","article-title":"Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis","volume":"105","author":"Oba","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2022.100572_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12885-020-06910-5","article-title":"Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials","volume":"20","author":"Nie","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2022.100572_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.esmoop.2022.100572_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100572_bib33","doi-asserted-by":"crossref","first-page":"833","DOI":"10.31128\/AJGP-07-19-4999","article-title":"Clinical Oncology Society of Australia position statement on cancer survivorship care","volume":"48","author":"Vardy","year":"2019","journal-title":"Aust J Gen Pract"},{"key":"10.1016\/j.esmoop.2022.100572_bib34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/ajco.13434","article-title":"Factors associated with fear of cancer recurrence in breast and colorectal cancer survivors: a cross-sectional study of cancer survivors","volume":"17","author":"Nahm","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100572_bib35","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jfma.2019.10.007","article-title":"Screening for fear of cancer recurrence: instrument validation and current status in early stage lung cancer patients","volume":"119","author":"Lee","year":"2020","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.esmoop.2022.100572_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jtho.2018.11.020","article-title":"The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: a post hoc analysis of the ADJUVANT trial (CTONG 1104)","volume":"14","author":"Xu","year":"2019","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:56Z","timestamp":1761856136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922002022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2059702922002022"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100572","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100572"}}